HC Wainwright Reiterates Buy Rating on Aclaris Therapeutics
HC Wainwright reiterated its Buy rating and $16 price target. The target implies 322.2% upside from the Oct. 27 close of $3.79.
Related stories
Rent.com.au Reports Quarterly Group Revenue of A$1.53 Million
M impact | EQUITY | Oct 30, 2026, 01:29 AM UTC
HanmiGlobal Wins 59.5 Billion Won Order
M impact | EQUITY | Oct 30, 2026, 01:29 AM UTC
Eoptolink opens 12.4% lower
Chinese optical-module producer Eoptolink opened 12.4% lower.
M impact | EQUITY | Oct 30, 2026, 01:29 AM UTC
Holista Colltech Reports Q3 FY2026 Group Revenue of A$1.58 Million
Holista Colltech reported group revenue of A$1.58 million for Q3 FY2026.
M impact | EQUITY | Oct 30, 2026, 01:29 AM UTC
Raon Robotics Q3 Operating Profit Rises 259.3% to 4 Billion Won
Raon Robotics reported Q3 operating profit of 4 billion won, up 259.3% from a year earlier.
M impact | EQUITY | Oct 30, 2026, 01:28 AM UTC
Doctor Care Anywhere Reports Q3 2026 Revenue of £11.3M
M impact | EQUITY | Oct 30, 2026, 01:28 AM UTC